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The peripheral nervous system mediates impulses between the body and the central nervous 
system (CNS). The peripheral neuropathies may be classified based on the distribution of the 
affected nerves, the nerve pathology, or on the pathogenesis. The term polyneuropathy 
describes disorders resulting from diffuse lesions in the peripheral nerves and typically 
presents as symmetrical sensory loss, pain, and weakness, most often starting distally. 
Autonomic dysfunction may also occur. Instrumental methods such as nerve conduction 
studies (NCS) and electromyography (EMG) are crucial to separate primary myogenic and 
neurogenic conditions, and give important information about the subclasses of peripheral 
neuropathies.  
 
1.1 Anatomy of the peripheral nervous system 
Only a short review of the most relevant elements is presented here, as details are broadly 
dealt with in numerous textbooks, among others Trepel, 1995 and Lippert, 1996. The somatic 
part of the peripheral nervous system transfer efferent motor impulses from the motor neurons 
of the spinal anterior horns to the skeletal muscles via the ventral roots enabling voluntary 
muscle contractions. Afferent and potentially conscious sensory impulses from the various 
sensory receptors of the periphery are transferred back to the dorsal horns of the medulla via 
the peripheral nerves, the pseudounipolar nerve cells of the spinal ganglions, and the dorsal 
roots.   
 
The autonomous part of the peripheral nervous system sustains important unconscious 
functions like respiration, and modulates the activity of the heart, intestines, glands and 
smooth muscles. Overall, the sympathetic nervous system has a mobilizing effect, whereas the 
parasympathetic nervous system rather triggers rest and digestion. From the lateral horn of the 
thoracolumbar medulla, nerves of the sympathetic nervous system reach the peripheral 
ganglia and subsequently the organs. The nerves of the parasympathetic nervous system 
originate from the brainstem and the lateral horn of the sacral medulla. A part of the nerve 
fibres serving autonomous functions are however also part of the peripheral nerves and 
trophic disturbances may therefore be a trait of chronic peripheral nerve dysfunction. 
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The peripheral nerves are enveloped in a membrane of connective tissue, and contain several 
sub-compartments that harbour the individual nerve fibres. The peripheral nerves may 
mediate a single afferent or efferent quality (motor, sensory or visceral), but they usually 
contain a mixture of nerve fibres supporting all of these functions. Somatic motor and sensory 
nerve fibres, and fibres involved in muscle reflexes are enveloped in multiple insulating layers 
of myelin produced by Schwann cells that follow the axons along their paths (Type A fibres). 
The space between each Schwann cell (nodes of Ranvier) allows the saltatory transmission of 
nerve signals from gap to gap enabling high nerve conduction velocities. The nerve fibres 
serving autonomic functions, or transferring the sensation of temperature or dull pain, are 
wrapped in few, or no layers of myelin (Type A delta/B/C fibres). As a consequence, the 
nerve conduction velocities are much slower.   
 
A single motor nerve innervates multiple muscle fibres (motor unit). There is extensive 
variation in the size of the motor units, particularly between muscles involved in fine and 
gross motor functions. The axons end in the synapse opposite of the specialised motoric 
endplates of the muscle membrane. The nerve signal triggers the release of acetylcholine that 
diffuses across the neuromuscular junction, and induces a cascade that generates a 
depolarisation of the muscle membrane and ultimately muscle contraction.  
 
1.2 Peripheral neuropathies 
Peripheral neuropathy, types of neuropathy, causes, and treatments are described in chapters 
of neurology textbooks (Mellgren, Rasmussen, & Vedeler, 2010). The nerve pathology may 
be restricted to a single nerve (mononeuropathy), to several individual nerves (multiple 
mononeuropathy), to a nerve plexus (plexopathy) or the nerve roots (radiculopathy). More 
commonly the nerve pathology may involve many peripheral nerves in a diffuse manner, 
usually earlier and more severe in the longest nerve fibres (distal symmetric polyneuropathy, 
“dying back neuropathy”). If only a single quality is involved, the neuropathy may be 
designated as a motor, sensory or autonomic neuropathy, whereas the combination of motor 
and sensory manifestations is called sensorimotor neuropathy. 
 
The polyneuropathy may primarily affect the axon or the myelin sheet. In both cases the 
lengthiest nerves are affected first resulting in a distal symmetric distribution of symptoms. 
These may be manifested as positive clinical symptoms such as increased or altered 
sensations of touch, pain or temperature, or negative clinical symptoms such as reduced 
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sensation of various qualities, weakened motor reflexes, muscle weakness, hypotonia and 
atrophy. The involvement of autonomic functions may lead to trophic disturbances, and in 
some cases central autonomic functions are also implicated.  
 
Finally, the underlying disease causes may be used to categorize the polyneuropathies into the 
following subgroups: genetic diseases, metabolic and endocrine conditions, malnutrition, 
polyneuropathy due to toxic substances or medications, infectious causes, connective tissue 
diseases, cancer, and immunologic diseases. All of these possible causations may be explored 
in a complete work up of a patient with polyneuropathy. If a disease cause is not found the 
polyneuropathy is classified as idiopathic, but a substantial proportion of so called idiopathic 
cases seem to be hereditary. 
 
1.3 Instrumental methods commonly applied in the assessment of polyneuropathies 
1.3.1 Nerve conduction studies (NCS) 
NCS of the thick, myelinated motor nerves are performed by inducing distal and proximal 
surface stimulation above the nerve through electrodes and registration of the motor response 
from multiple individual muscle fibres of the innervated muscle (Sand & Jørum, 2010).  The 
time elapsed between the stimulation and the muscle reaction (distal latency) is measured 
(ms) as well as the size of the reaction (motor amplitude) (mV). The latter is an expression of 
the number of recruited nerve cells and axons. The physical distance between the points of 
proximal and distal stimulation, combined with the difference in distal latency are used to 
assess the motor nerve conduction velocity (MNCV) (m/s). The nerve impulse produced at 
the electrode is transferred in orthodromic direction towards the muscle, as well as antidromic 
towards the cell bodies in the anterior horn. A second, lesser response from the muscle (F-
response) is caused by a reflection of the signal back from the anterior horns. As a 
consequence the NCS may also give information about the proximal part of the peripheral 
nerves and in particular, the nerve roots. The distal latency, amplitude and conduction 
velocities can also be assessed for sensory nerves. Nerves commonly evaluated in 
polyneuropathy cases are the median and ulnar nerve of both arms, and the peroneal, posterior 
tibial and sensory sural nerve of one of the legs. 
 
A reduction in the motor nerve conduction velocity in combination with (almost) normal 
amplitude is indicative of a demyelinating pathologic process. The opposite, a (near) normal 
motor nerve conduction velocity and small (or absent) motor amplitudes indicates axonal 
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pathology. As the disease progresses however, signs of both types are usually registered due 
to a mixture of both demyelinating and axonal pathologic processes. 
 
1.3.2 Electromyography (EMG) 
EMG is an invasive method that is based on the insertion of needle electrodes into the muscle 
under study (Sand & Jørum, 2010). An individual nerve innervates multiple muscle fibres 
(motor unit) and at voluntary contraction the response from that group of fibres may be 
assessed as motor unit potentials (MUP), either visually on the computer screen, or 
acoustically over loud speakers. The width (ms) and height (µV) of a single MUP is 
registered, as well as the activity (Hz) under resting conditions, and the pattern of recruitment 
associated with increasing contraction.  
 
In primary myogenic conditions the motor units are preserved, but the muscle pathology leads 
to small MUPs with short duration. With contraction a high frequency of small MUPs are 
quickly recruited. No signals are normally registered under resting conditions. Denervation 
destabilizes the membrane potentials in the respective motor units however, leading to an 
intermittent period with spontaneous activity seen as fibrillations and positive sharp waves. 
These are characteristic for acute and sub acute nerve damage. In subacute and chronic 
conditions signs of reinnervation are also increasingly registered in the form of wider, higher 
and often polyphasic MUPs. With contraction MUPs are few, but large. In motor neuron 
diseases such as ALS, nerve conduction studies may show results quite similar to the axonal 
polyneuropathies. The EMG however, mostly exhibits more denervation activity; 
fasciculation’s and signs of reinnervation.  
 
1.3.3 Quantitative sensory testing 
Quantitative sensory testing (Thermotest) evaluates thin fibres mediating cold and heat by 
defining subjective thresholds for cold and heat sensation (Sand & Jørum, 2010). However, 
skin biopsy with determination of epidermal nerve fibre density is more objective for 
demonstration of small fiber neuropathy (Mellgren, Nolano, & Sommer, 2013).  
 
2 Inherited polyneuropathies and related conditions 
Inherited polyneuropathies are often an element of a more complex phenotype that is caused by 
illnesses such as a mitochondrial disease, a genetic syndrome or a metabolic disorder, or the 
neuropathy may be the only symptom, most often manifesting as a distal symmetric 
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polyneuropathy (Reilly, 2007). Distal symmetric polyneuropathy is common and can have a 
number of causes including various underlying conditions, environmental or inheritable factors. 
The population prevalence is around 2.4 %, in the subgroup aged 55 years or older it is assessed 
to 8 % (Martyn & Hughes, 1997).  In half of the cases the underlying disease is found after 
neurologic investigation, but the rest remain idiopathic (Dyck, Oviatt, & Lambert, 1981). A large 
part of the idiopathic cases are genetic (40 %), Charcot Marie Tooth (CMT) is the most frequent 
entity and makes up about half of this group (Dyck et al., 1981; Ouvrier & Nicholson, 1995).  
 
CMT mainly involves the large and myelinated peripheral motor and sensory nerve fibres, but 
some small fibre involvement has been reported (Krajewski et al., 2000; Zambelis, 2009). 
Clinically and neurophysiologically it is distinguished from the distal hereditary motor 
neuropathies (dHMN) that are associated with motor symptoms without sensory loss, and the 
hereditary sensory and autonomic neuropathies (HSAN) that are associated with 
predomination of sensory symptoms. Diseases such as hereditary spastic paraplegia and 
primary lateral sclerosis mainly implicate the upper motor neurons (UMNs) whereas 
progressive muscular atrophy and spinal muscular atrophy involve the lower motor neuron 
(LMN). Amyotrophic lateral sclerosis (ALS) involves both UMNs and LMNs. Some ALS 
subtypes are also associated with frontotemporal dementia (FTD) (Pan & Chen, 2013; Renton 
et al., 2011). 
 
The classification of these genetic diseases is, in addition to the clinical signs, based on 
inheritance patterns and underlying gene defects. Classification systems that are based on 
clinical symptoms may not correlate well with those based on biology. In the World Muscle 
Society’s gene table (http://www.musclegenetable.fr/), 283 genes were distributed on 16 
groups of neuromuscular disorders, 47 associated with variants of CMT and HSAN, 14 with 
dHMN or dSMA and 15 with subtypes of familial ALS (FALS) (Kaplan, 2011). Many of 
those genes are linked with multiple disease classes: Three genes are associated with ALS and 
FTD (VCP, UBQLN2 and c9orf72), two with ALS and HMN (VAPB, SETX), one with ALS 
and CMT (FIG4), one with ALS, spastic paraplegia and primary lateral sclerosis (ALS2), six 
with HMN and CMT2 (DYNC1H1, TRPV4, GARS, AARS, HSPB1 and HSPB8), two with 
HMN and spastic paraplegia (REEP1 and BSCL2), and one with hereditary sensory 
neuropathy (HSN) and spastic paraplegia (KIF1A) (Sivakumar et al., 2005). Several SOD1 
mutations are linked to phenotypes with long survival and absent UMN symptoms, fulfilling 
the ALS criteria, but with a prognosis different from that normally associated with ALS 
 12
(Brooks, Miller, Swash, & Munsat, 2000). Some SOD1 mutations may also be associated with 
marked sensory disturbances that contradict a diagnosis of ALS (Rezania et al., 2003).  
 
The large number of genes that may cause a CMT phenotype necessitates extensive testing if 
one is to examine all possible causations. Moreover, even the exclusion of all CMT associated 
genes would be insufficient due to the variance in phenotypes associated with single genes. 
That particularly applies for genes primarily associated with conditions affecting neurons with 
long axons such as HSAN, HMN, ALS and HSP. Furthermore, all known genes combined 
only explain a proportion of the heritability, particularly in the case of axonal CMT where 
many disease associated genes remain unknown.  
 
3 Charcot Marie Tooth disease (CMT) 
Based on nerve conduction studies CMT with dominant inheritance is divided into CMT1 and 
CMT2. CMT1 is associated with demyelination and reduced nerve conduction velocities while 
CMT2 has (near) normal velocities due to axonal pathology.  A MNCV cut-off of 38 m/s in the 
N. medianus is commonly used to separate the two forms (Harding & Thomas, 1980). Recessive 
CMT is labelled CMT4, and X-linked cases CMTX independent of results on NCS. 
 
The prevalence of the CMT phenotype has been estimated to 10-20:100000 globally (Emery, 
1991). Locally, in the population of Western-Norway the prevalence has been reported to be 
41:100000 (Skre, 1974), in Eastern-Norway (Akershus) 1:1214 (Braathen, Sand, Lobato, 
Hoyer, & Russell, 2011), and in Northern-Sweden 20:100000 (Holmberg, 1993). CMT 
primarily implicates the peripheral nerves, classically occurring earlier and more 
predominantly in the lower than in the upper limbs. Onset is mostly before 20 years of age, 
but there is sizable variation in debut as well as severity, particularly in CMT2 cases (Harding 
& Thomas, 1980). In most cases however, the symptoms are benign and slowly developing 
(Carter et al., 1995). In the classic phenotype, muscular atrophy and weakness in the distal 
parts of the legs, absence of Achilles tendon reflexes, pes cavus and hammer toes are typical 
findings.  
 
CMT subtypes are designated by the causative gene defect and the number of subtypes is 
growing rapidly, particularly in the case of CMT2. A classical presentation of the CMT1 and 
CMT2 phenotype cannot accurately be divided on the basis of clinical signs (Bienfait et al., 
2006). Most CMT2 patients have the classical phenotype and the underlying gene defect can 
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only be revealed in a subfraction of those cases, usually through the detection of a MFN2 
mutation. Some of the CMT2 cases may present with asymmetric muscle weakness, 
hypertrophy of the calves, Babinski’s sign, hyperreflexia or other manifestations that do not 
suit the classical CMT phenotype (Bienfait et al., 2007). Especially severe phenotypes with 
early onset and very slow MNCVs are sometimes designated as Dejerine-Sottas syndrome 
(DSS, MIM 145900) or congenital hypomyelinating neuropathy (CHN, MIM 605253). 
Genetically they are heterogeneous and autosomal dominant as well as autosomal recessive 
transmissions have been described.  
 
3.1 Charcot Marie Tooth Neuropathy Type 1 (CMT1) 
CMT1 compose approximately 50 % of the total CMT group and most cases can be identified 
with molecular genetic testing. There are 6 genetically defined subclasses (Table 1). CMT1A 
due to a duplication of the PMP22 region is by far the most common constituting around 70 




Patients with a duplication of the PMP22 region mostly present a classical CMT phenotype, 
but varying graveness of symptoms is typical, even among members of an individual family. 
The reported phenotypes spans from congenital onset and severe symptoms to clinically 
unaffected (Birouk et al., 1997; Baets et al., 2011), but the median MNCV is virtually always 
< 38 m/s (Birouk et al., 1997; Bienfait et al., 2006; Marques, Jr. et al., 2005; Kim et al., 2012). 
Hand tremor, hearing loss, scoliosis, calf hypertrophy, pain, diaphragmatic weakness, 
hypoesthesia and even brain involvement with cognitive impairment are among additional 




MPZ mutations may cause demyelination and a severe clinical phenotype with very slow 
MNCVs (DSS, CHN) or they may generate axonal pathology and a milder CMT1/2 
phenotype with intermediate or axonal range MNCVs (Shy et al., 2004). Some mutations are 
associated with particular phenotypic traits such as pupillary abnormalities, auditory 
neuropathy and tremor (Shy et al., 2004; Mandich et al., 2009a; Chapon, Latour, Diraison, 
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Schaeffer, & Vandenberghe, 1999; Starr et al., 2003; Plante-Bordeneuve, Guiochon-Mantel, 
Lacroix, Lapresle, & Said, 1999). 
 
3.2 Charcot Marie Tooth Neuropathy Type 2 (CMT2) 
CMT2 composes about 20 % of the CMT group (Harding & Thomas, 1980). Mutations in the 
MFN2 gene is the most frequent and may account for 10-30 % of the classical CMT2 cases in 
many ethnicities (Zuchner et al., 2004; Lawson, Graham, & Flanigan, 2005; Verhoeven et al., 
2006; McCorquodale, III et al., 2011). Disease causing mutations in other CMT2 associated 
genes are individually rare. These consist of 14 genes and 1 locus in which the involved gene 
has not been identified (Table 1). 
 
3.2.1 CMT2A 
MFN2 mutations are usually associated with a classical CMT2 phenotype. Postural hand 
tremor, sensorineural hearing loss, pain and signs of UMN involvement like Babinski’s sign 
or hyperrefexia are among additional features that have been reported (Chung et al., 2006; 
Chung et al., 2010; Zhu et al., 2005). Some however, experience a very severe phenotype that 
sometimes includes optic atrophy and they frequently have an early onset (< 10 years) 
(Zuchner et al., 2006; Chung et al., 2006). The severe phenotype may also include scoliosis, 
knee contractures or brain involvement. In contrast, mutation carriers that are mildly affected 
or asymptomatic may also be observed in some families (Lawson et al., 2005). A recessive 
pattern of inheritance has been reported (Polke et al., 2011). 
 
3.3 Dominant intermediate Charcot Marie Tooth Neuropathy (DI-CMT) 
A dominant intermediate phenotype also exists. The intermediate range MNCVs are between 
25 and 45 m/s and different members of DI-CMT families exhibit MNCVs within both axonal 
and demyelinating ranges (Nicholson & Myers, 2006). Some genes (DNM2, YARS) are 
primarily associated with this type. The MPZ gene is associated with DI-type D in addition to 
CMT1B, 2I/J and 4E. A forth gene associated with DI-CMT (GNB4-related I-CMT) was 
recently identified. DI-CMT type A has been mapped to10q24-25, but the gene in question 
remains to be identified (Table 1). Mutations in many of the genes traditionally associated 
with other groups may also cause MNCVs in the intermediate range, this particularly holds 




3.4 Charcot Marie Tooth Neuropathy Type X (CMTX) 
Genes involved in CMTX are located on the X-chromosome. Two genes involved in X-linked 
dominant CMT (GJB1, PDK3), as well as two genes (PRPS1, AIFM1) and two loci associated 
with X-linked recessive CMT have been identified (Table 1).  
 
3.4.1 CMTX1 
The GJB1 gene (CMTX1) is a major cause of CMT and responsible for most of the CMTX 
cases and also about 10 % of the total CMT group (Boerkoel et al., 2002). Males are on 
average more gravely affected than females who typically exhibit slow or intermediate range 
MNCVs. Females may be healthy or mildly affected, and usually have intermediate or axonal 
range MNCVs (Dubourg et al., 2001b; Dubourg et al., 2001a). Upper limb tremor and 
sensorineural hearing loss are additional symptoms that have been reported with some 
frequency. Some papers describe rare episodes of CNS disease after provocations such as 
infections or hyperventilation, but persistent CNS involvement like Babinski’s sign or 
alterations in the corticospinal tract on MRI have also been reported (Srinivasan, Leventer, 
Kornberg, Dahl, & Ryan, 2008; Marques, Jr., Sweeney, Wood, Wroe, & Marques, 1999; 
Kassubek, Bretschneider, & Sperfeld, 2005; Siskind, Feely, Bernes, Shy, & Garbern, 2009). 
 
3.5 Charcot Marie Tooth Neuropathy Type 4 (CMT4) 
Nine genes have been associated with the recessive CMT4 (Table 1). The phenotype is 
severe, has an early onset and may include manifestations such as diaphragmatic weakness, 
scoliosis, hearing loss or glaucoma. In some areas CMT4 may be responsible for as much as 
40 % of the CMT group, but in the Northern-European population the recessive forms have 
been assumed to be rare (Reilly, 2007). 
 
3.5.1 CMT4A  
The GDAP1 gene is causative of one of the most common subclasses of CMT4 (CMT4A), but 
also the rare dominant CMT2K. The CMT4A cases have an early onset of severe symptoms 
and some eventually become dependent on a wheelchair. A fraction of the diseased also 
experiences vocal cord paresis and weakened diaphragm. Axonal range MNCVs is typical, 
but intermediate or even demyelinating range MNCVs may occur in patients with grave 





The SH3TC2 gene is linked to the other relatively common subclass of CMT4 (CMT4C). The 
phenotype is usually severe with early onset and often includes scoliosis (Azzedine et al., 
2006). MNCVs are in the demyelinating range. Hypomyelination and extended Ranvier's 
nodes have been observed on nerve biopsy (Arnaud et al., 2009). In some ethnicities CMT4C 
is responsible for many cases of demyelinating CMT, but in a recent report from the UK the 




























Table 1. CMT1, CMT2, DI-CMT, CMTX and CMT4 with their subtypes, associated genes or loci and 
protein products, if known (Bird, 2014).  
 
CMT subgroup Gene/Locus Protein 
CMT1A PMP22  Peripheral myelin protein 22 
CMT1B MPZ  Myelin P0 protein 
CMT1C LITAF  Lipopolysaccharide-induced tumor necrosis factor-alpha factor 
CMT1D EGR2  Early growth response protein 2 
CMT1E PMP22  Peripheral myelin protein 22 (sequence changes) 
CMT1F/2E NEFL  Neurofilament light polypeptide 
CMT2A1 KIF1B  Kinesin-like protein KIF1B 
CMT2A2 MFN2  Mitofusin-2 
CMT2B RAB7A Ras-related protein Rab-7 
CMT2B1 LMNA  Lamin A/C 
CMT2B2 MED25 Mediator of RNA polymerase II transcription subunit 25 
CMT2C TRPV4 Transient receptor potential cation channel subfamily V member 4 
CMT2D GARS  Glycyl-tRNA synthetase 
CMT2E/1F  NEFL  Neurofilament light polypeptide 
CMT2F HSPB1  Heat-shock protein beta-1 
CMT2G 12q12-q13 Unknown 
CMT2H/2K GDAP1 Ganglioside-induced differentiation-associated protein-1 
CMT2I/2J MPZ Myelin P0 protein 
CMT2L HSPB8  Heat-shock protein beta-8 
CMT2N AARS Alanyl-tRNA synthetase, cytoplasmic 
CMT2O DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 
CMT2P LRSAM1 E3 ubiquitin-protein ligase LRSAM1 
DI-CMTA 10q24.1-q25.1 Unknown 
DI-CMTB DNM2  Dynamin 2 
DI-CMTC YARS  Tyrosyl-tRNA synthetase 
DI-CMTD MPZ Myelin P0 protein 
GNB4-related  I-CMT GNB4 Guanine nucleotide-binding protein subunit beta-4 
CMTX1  GJB1  Gap junction beta-1 protein (connexin 32) 
CMTX2 Xp22.2 Unknown 
CMTX3 Xq26 Unknown 
CMTX4 AIFM1  Apoptosis-inducing factor 1 
CMTX5 PRPS1 Ribose-phosphate pyrophosphokinase 1 
CMTX6 PDK3 Pyruvate dehydrogenase kinase isoform 3 
CMT4A GDAP1  Ganglioside-induced differentiation-associated protein 1 
CMT4B1 MTMR2  Myotubularin-related protein 2 
CMT4B2 SBF2  Myotubularin-related protein 13 
CMT4C SH3TC2  SH3 domain and tetratricopeptide repeats-containing protein 2 
CMT4D NDRG1  N-myc downstream-regulated gene 1 protein 
CMT4E EGR2  Early growth response protein 2 
CMT4F PRX  Periaxin 
CMT4H FGD4 FYVE, RhoGEF and PH domain-containing protein 4 




4 Pathomechanisms and therapy 
4.1 Pathomechanisms 
Some of the genes linked to the CMT phenotype encode proteins that are located in, or are 
particularly important for specific parts of the peripheral nervous system (PNS) (Figure 1). 
Examples are for the compact myelin PMP22 and MPZ, non-compact myelin GJB1, neuronal 
cell body LMNA and axons NEFL. Many of the genes are expressed in several tissues 
however (EGR2, GARS, DNM2, RAB7, MFN2, GDAP1, LMNA, NEFL), and it is not known 
why their defects mainly or solely implicate the PNS. Functional attributes of the nerves are 
the extraordinary need of energy, the neuronal transmission, and their systems for 
transportation along the long axons. All of these functions represent possible explanations. 
The latter attribute in particular fits the length dependence of the polyneuropathy seen in most 
CMT phenotypes (Juarez & Palau, 2012; Patzko & Shy, 2011; Zuchner & Vance, 2006).  
 
In rare cases the neuropathy is caused by an inborn distortion of the myelination that can be 
observed on nerve biopsy as hypomyelination without current de- and regeneration (MIM 
605253). More commonly there is a secondary myelin involvement that in grave cases is 
visible on nerve biopsy as hypertrophic nerves with onion bulbs as tokens of current de- and 
regeneration (MIM 145900). Axonal damage ultimately explains the neuropathy in 
myelinated fibres seen in CMT2 as well as in CMT1. In CMT2 axons are directly implicated 
whereas in CMT1 they are involved through intercommunication with the Schwann cells 
(Krajewski et al., 2000). Nerve biopsy does not currently have a prominent role in the 
diagnostics of CMT however. 
 
The disease mechanism may be a gene dosage effect such as the over expression observed in 
CMT1A or the haploinsufficiency causative of hereditary neuropathy with liability to pressure 
palsy (HNPP). In other cases the disease mechanism is not linked to normal gene function, but 
rather to a toxic gain of function mechanism. Animal models such as the rat, mouse, fruit fly 
and others have been helpful in studies of these mechanisms (Sereda & Nave, 2006; 
Eschenbacher et al., 2012). 
 
Many of the proteins encoded by genes linked to the CMT phenotype have similar functions 
and some may have underlying disease mechanisms in common. Implicated functions are 
compaction, preservation and construction of myelin (PMP22, MPZ), transportation along 
axons (KIF1B, MFN2, NEFL, GDAP1), transcription of genes (EGR2), functioning of 
 19
mitochondria (MFN2, GDAP1), synthesis of tRNA (AARS, KARS, GARS, YARS), molecular 
chaperoning (HSP27, HSP22), trafficking through membranes (MTMR2, MTMR13), 
functioning of endosomes (RAB7, SH3TC2), construction of the cytoskeleton (NEFL) and 
channelling of ions (GJB1, TRPV4). (Juarez & Palau, 2012; Patzko & Shy, 2011; Zuchner & 
Vance, 2006). Many of the same metabolic pathways and protein functions have evenly been 
linked to related inherited phenotypes that also implicate long axons, for example HSAN, 
HMN, HSP and ALS (Timmerman, Clowes, & Reid, 2013). 
 
In contrast, the phenotype may vary considerably between different mutations in the same 
gene, which in some cases can be explained by the involvement of different 
pathomechanisms. Mechanisms implicated in association with various MPZ mutations include 
(partial) loss of function, dominant negative effects and gain of glycosylation (Grandis et al., 
2008; Wrabetz et al., 2006; Mandich et al., 2009b; Lee et al., 2010; Prada et al., 2012). The 
genomic architecture bordering the 1.4 Mb PMP22 region on chromosome 17p12 predisposes 
to duplications/deletions due to unequal crossing over (Inoue et al., 2001). In the case of 
CMT1A that results in a gene dosage effect with over expression of the PMP22 gene in all 
CMT1A patients. However, other inborn genetic variants are postulated to play a major 
regulatory role influencing the level of expression, possibly explaining some of the clinical 
variation. Some of these regions have been identified (Jones et al., 2012). GJB1 encodes a gap 
junction protein (connexion 32) which is not only expressed in Schwann cells, but also in 
oligodendrocytes, possibly explaining the CNS manifestations exhibited by some of the 
patients. Most of the sequence variants in GJB1 lead to protein retention in the endoplasmatic 
reticulum and loss of function (Sargiannidou et al., 2009). Mitofusin 2 plays a key role in the 
fusion of outer mitochondrial membranes, compulsory for the admixture of molecules and 
mtDNA amongst different mitochondria. Defects in mitofusin 2 function may impair the 
replication of mtDNA, ultimately leading to mtDNA depletion (Vielhaber et al., 2013). 
Impaired mitochondrial transport can also be an important mechanism in MFN2 associated 
disease. It may for example limit the adjustability to local variations in the energy demand 
along the axons resulting in intermittent local hypoxia and ultimately Wallerian degeneration 
(Misko, Sasaki, Tuck, Milbrandt, & Baloh, 2012). The potential importance of defective 
axonal transport in ALS and other neurodegenerative disorders has been reviewed (Morfini et 
al., 2009). With regard to SOD1 associated FALS several mechanisms have been proposed, 
all implicating a dominant negative (toxic) effect. As in the case of MPZ associated CMT, 
different pathomechanisms may apply for different mutations. A peculiarity of the p.H47R 
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substitution is that it changes one of the four histidines that bind copper in the active site, 
severely disturbing normal enzyme function (as an antioxidant) (Antonyuk et al., 2005; 
Winkler et al., 2009; Pan et al., 2012). However, the molecular reason for the benign CMT2-
like clinical course associated with p.H47R is not clear. 
 
 
Figure 1: Figure displaying the neuron, axon, Schwann cell and many of the genes 
involved in CMT and related phenotypes as well as suggested pathomechanisms (Rossor, 
Polke, Houlden & Reilly, 2013). 
Reprinted by permission from Macmillan Publishers Ltd: Nat. Rev. Neurol. Volume 9, 2013, 
562-571, copyright 2013. 
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4.2 Therapy 
The genetic investigations and the study of relevant pathomechanisms aim at developing 
causal treatment. That may require complicated procedures that intend to manipulate 
pathomechanisms directly such as the silencing of toxic gain of function mutations or 
mutations that cause over expression or oppositely, stimulation of protein production in 
disorders induced by haploinsufficiency. Other approaches seek to limit neuronal 
degeneration and activate regeneration independent of the involved pathomechanisms. The 
role of animal models has recently been reviewed (Bouhy & Timmerman, 2013). One 
intervention study that has reached clinical trials is the dietary treatment of HSN type 1 with 
oral L-Serine (ClinicalTrials.gov Identifier: NCT01733407) (Garofalo et al., 2011). Examples 
of completed studies, regrettably without documented effect, are treatment of patients with the 
CMT phenotype with coenzyme Q10 (ClinicalTrials.gov Identifier: NCT00541164) and 
treatment of CMT1A patients with high dose ascorbic acid (ClinicalTrials.gov Identifier: 
NCT00484510/NCT00271635) (http://clinicaltrials.gov/ct2/home) (Lewis et al., 2013). High 
throughput tools have been developed that search for agents that can influence regions 
regulating PMP22 expression (Jang, Lopez-Anido, MacArthur, Svaren, & Inglese, 2012).The 
detailed diagnostic studies at neuromuscular centres should aim at having patients ready for 
relevant clinical trials and treatments as they develop.  
 
5 Challenges in genetic testing of patients with CMT  
Diagnostic testing for CMT presents a number of challenges for laboratories because: (i) 
many different genes are associated with CMT; (ii) mutations in a single gene may cause 
different clinical pictures, while mutations in different genes linked to the CMT phenotype 
can cause identical symptoms; (iii) family history might be absent; (iv) the laboratories 
receive DNA and clinical information from many medical doctors of diverse specialities and 
clinical backgrounds; (v) important clinical information might be sparse or absent and; (vi) 
the sensitivity of CMT2 testing is low. Furthermore, a broad scanning of a large number of 
patients takes a lot of resources and gives a low yield of positive genetic test results. 
 
5.1 Genetic testing of patients with CMT 
Recommended procedures for molecular genetic CMT testing presupposes exact clinical 
details, detailed results from NCS and thoroughly sampled family histories collected under 
good clinical conditions. They are therefore well suited for inherited polyneuropathy clinics 
(England et al., 2009; Saporta et al., 2011; Murphy, Laura, & Reilly, 2013). In the everyday 
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practice for laboratories investigating external samples such favourable circumstances are 
rarely found and as a consequence, the mutational yield in that group is significantly lower 
(Murphy et al., 2012). In Norway most patient samples are tested in this setting, and in a 
recent report from a Neuromuscular Clinic in the UK almost 2/3rds of the tested samples were 
external (Murphy et al., 2012). In spite of the differences in the context for testing, in depth 
studies of external samples are lacking. With regards to the guidelines however, the two 
groups are frequently treated as if they were identical. In paper I we document that > 90% of 
the mutations are found in PMP22, MPZ, MFN2 and GJB1, and several other groups have 
made similar observations (Murphy et al., 2012; Saporta et al., 2011). For screening of 
external samples, the established algorithms may be too extensive, but for the thorough work-
up of patients at neuromuscular centres they may be too limited considering the technology 
that recently has become available.   
 
5.2 Challenges in the classification of sequence variants 
Diagnostic laboratories investigate genes with known association to particular monogenic 
Mendelian phenotypes. Sequence variants such as nonsense mutations, frame-shifting 
deletions/insertions and variants affecting canonical splice-sites are predicted to disrupt gene 
function and they are generally considered pathogenic. This is also the case for missense 
variants that repeatedly have been identified in patients but not in controls.  Sequence variants 
that have been frequently observed in large control panels are usually considered benign. All 
other sequence variants are of uncertain clinical significance. This suggests that a 
classification system with three levels, distinguishing between pathogenic, non-pathogenic 
and uncertain variants, would be appropriate. For variants of uncertain clinical significance 
(VUS) different types of documentation may be collected to elucidate their clinical relevance 
further. Testing of control samples and assessment of the allele frequency in single nucleotide 
polymorphism (SNP) databases are powerful standard methods to exclude pathogenicity. The 
documentation of non-segregation in clinically well-defined families, and the documentation 
of lacking amino acid conservation among species may also help weakening the probability of 
clinical significance. It is more difficult to obtain support for the clinical relevance of a 
variant. However, in isolated CMT cases the observation of a de novo variant in a known 
CMT associated gene is substantial evidence for its pathogenicity (Richards et al., 2008; 
Sunyaev, 2012). In the diagnostic laboratory potential splice site mutations may be 
investigated with mRNA studies. In some neuromuscular disorders functional studies are 
currently used in routine diagnostics, for example on muscle biopsies. For CMT associated 
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genes however, the availability of functional studies is limited (Bell, Bodmer, Sistermans & 
Ramsden, 2007) 
We used Alamut (http://www.interactive-biosoftware.com/) as an initial tool in the 
assessment of all the genetic variants identified in this study. Alamut works as a web browser 
with the gene under investigation as the focal point. Evidence related to a particular sequence 
variant in the gene is collected from multiple sources and subsequently incorporated and 
presented. These include data from: dbSNP from The National Center for Biotechnology 
Information (http://www.ncbi.nlm.nih.gov/SNP/), The Human Gene Mutation Database 
(HGMD Professional) (http://www.hgmd.org/) as well as the Exome Variant Server of the 
NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/). Powerful statistical 
evidence is obtained through investigations of the minor allele frequency (MAF) of a 
particular variant in the populations included in the databases. Variants that previously have 
been reported as (likely) pathogenic are highlighted in the reference sequence and individual 
reports are accessible via links to the HGMD. Extended literature searches are also mediated 
through PubMed (http://www.ncbi.nlm.nih.gov/pubmed) and Google 
(http://www.google.com). The proof collected from epidemiological data and earlier reports 
on affected patients often have the power to justify a primary classification of a missense 
mutation as (likely) pathogenic/non-pathogenic. In some cases published results on functional 
studies may also influence the interpretation of a particular sequence variant.  
 
In many cases, however, these sources alone do not provide enough proof to classify a 
missense mutation as (likely) pathogenic/non-pathogenic. Reports on how to interpret 
uncertain variants in CMT have been sparse, but the subject has been studied thoroughly in 
relation to breast cancer. Up to half of the variants in BRCA1/2 are of uncertain clinical 
relevance (Gomez Garcia et al., 2009). The International Agency for Research on Cancer 
(IARC) Unclassified Genetic Variants Working Group favoured a division of interpretations 
in genes linked to cancer into five; 5 = definitely pathogenic, 4 = likely pathogenic, 3 = 
uncertain, 2 = likely not pathogenic, 1 = definitely not pathogenic (Plon et al., 2008). In this 
manner the large group of variants of unspecific significance in the classification system with 
three levels is divided into three groups (2-4) allowing more specific communication of 
probability levels, although final proof for or against pathogenicity is lacking.  
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Alamut integrates several prediction tools that assist in the interpretation of variants of 
unknown clinical significance. The conservation of a nucleotide or more importantly, of an 
amino acid, is understood as a sign of functional importance. Conservation scores are 
estimated from the degree of variation between DNA and amino acid sequences (AAS) from 
orthologues of growing phylogenetic distance, from human to yeast. DNA and protein 
annotations as well as structural data, where available, also provide important input into some 
of the interpretation tools. Grantham scores for individual amino acids are assessed from 
physiochemical properties such as size, polarity, hydropathy, charge, etc (Ng & Henikoff, 
2006). More specifically, align GVGD is a prediction tool supplied by the IARC 
(http://agvgd.iarc.fr/). It estimates a Grantham score and multiple AAS alignments from 
orthologues are compared to estimate the degree of variation for a particular amino acid 
(Grantham Variation). The distance between the Grantham score of the substitute amino acid 
and the average score of the Grantham Variation is expressed in the Grantham Distance (GD). 
An increase in the GD is interpreted as an increased likelihood of pathogenicity (Tavtigian et 
al., 2006; Mathe et al., 2006). SIFT (sorting intolerant from tolerant) is a tool supplied by the 
J. Craig Venter Institute (http://sift.jcvi.org/). It also evaluates physiochemical properties of 
amino acids and the degree of conservation in orthologues (Sim et al., 2012). PolyPhen-2 (the 
prediction of functional effects of human nsSNPs) is supplied by the Harvard Medical School 
(http://genetics.bwh.harvard.edu/pph2/). A complicated algorithm includes data such as the 
DNA sequence, amino acid sequence and structural data in humans, as well as comparisons 
between orthologues (Adzhubei et al., 2010; Adzhubei, Jordan, & Sunyaev, 2013). 
MutationTaster is provided by the National Genetics Reference Laboratory Manchester 
(http://www.mutationtaster.org/). It incorporates results from other prediction tools in an 
interface, and uses Bayesian principles to estimate a common prediction (Schwarz, 
Rodelsperger, Schuelke, & Seelow, 2010). SwissProt is supplied by the Swiss institute of 
Bioinformatics (http://web.expasy.org/docs/swiss-prot_guideline.html). It is a validated 
version of the UniProt Knowledgebase, and provides quality data regarding AAS and protein 
structure, function, localization and interactions (Bairoch, Boeckmann, Ferro, & Gasteiger, 
2004). However, there are still extensive gaps in the coverage provided by SwissProt. Alamut 
evenly incorporates multiple tools that can assess the potential splice site effect of sequence 
variants in silico. These include SpliceSiteFinder-like, MaxEntScan, NNSPLICE and Human 
Splicing Finder (http://www.interactive-biosoftware.com/alamut/doc/2.3/splicing.html). The 
predictions from the different programs vary, and the results are often contradictive. The 
results must therefore be interpreted with care and the final decision on mutation class must 
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be computed manually. The reports from the interpretation tools serves as decisional support 
and in themselves, they do not provide sufficient evidence to alter the interpretation of a 
sequence variant of unknown pathogenicity.  
 
5.3 Extended diagnostic studies  
It is demanding to sort out the patients where a large genetic contribution is credible and the 
cases where extended testing should be performed. If a positive family history is missing in a 
polyneuropathy patient, phenotypic characteristics like early onset, sensory symptoms, pes 
cavus, hammertoes and slowly evolving disease may help selecting cases for testing of the 
prevalent genes (PMP22dup, MPZ, GJB1, MFN2) (Reilly, 2007). On the other hand, unusual 
phenotypes increase the likelihood of association with a rare CMT gene. The recent 
technological development enables detection of rare, very rare and even new disease causing 
genes. As such there is a gradate shift from diagnostics to research and vice versa. Quality 
control measures and the use of registers should accompany this development.  
 
5.3.1 Targeted testing  
Specific handles such as ethnicity or particular clinical clues may help pinpointing cases 
where a major genetic contribution is likely and may also enable targeted testing of a limited 
number of rare candidate genes. Examples are Dejerine Sottas Syndrome (MPZ, EGR2, 
PMP22, PRX), congenital hypomyelinating neuropathy (MPZ, EGR2), axonal CMT with 
Argyl Robertson pupil (MPZ), upper limb predominance of weakness with or without sensory 
findings (GARS, BSCL2) – or with spasticity (BSCL2), pronounced sensory loss and 
insensitivity to pain (RAB7), vocal cord paresis (GDAP1, TRPV4), or intermediate range 
MNCVs and glomerulopathy (IFN2) (http://www.musclegenetable.fr/) (Boyer et al., 2011). 
Only a small fraction of the patients seen in inherited polyneuropathy clinics belong to that 
group however.  
 
5.3.2 Linkage studies and massive parallel sequencing  
Parallel sequencing of all the protein coding regions of the genome (exome sequencing) was 
presented as a way to uncover mutations in rare monogenic disorders in 2009, revealing the 
mutations in four individuals with Miller syndrome in 2010 (Ng et al., 2009; Ng et al., 2010). 
These next generation sequencing methods (NGS) are especially advantageous in the 
diagnostics of multifarious phenotypes like CMT and other heterogeneous neuromuscular 
disorders. This was first illustrated in a family with a GJB1 mutation, and subsequently in 
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many other research publications (Montenegro et al., 2011; Choi et al., 2012; Landoure et al., 
2012; Weedon et al., 2011; Weterman et al., 2012; Kennerson et al., 2013). At present NGS is 
increasingly incorporated into the repertoires of regular diagnostic laboratories and practical 
approaches have already been discussed extensively in the literature (Vasli et al., 2012; Vasli 
& Laporte, 2013). In large dominant, X-linked or consanguineous families, traditional linkage 
studies may help identifying candidate regions for further analysis with NGS. It is not 
necessary to obtain the high significance levels traditionally used (LOD > 3) for that purpose. 
Similarly, analysis of copy number variation and the identification of homozygous regions 
may help prioritizing candidate genes in recessively inherited cases.  
      
5.4 Family investigations 
Genetic diagnostic evaluations of index patients with the CMT phenotype have been 
comprehensively reported. The subsequent molecular genetic family investigations however, 
have received less focus. Diagnostic, presymptomatic and prenatal testing is feasible for 
variants with definite or likely pathogenicity, in some cases also preimplantation diagnostic 
testing (PGD). Predictive and prenatal testing of the common CMT linked genes are affiliated 
with psychological and ethical issues. Medically, the broad clinical variation, even amongst 
family members might create uncertainty. Furthermore, the medically defined gravity of the 
phenotype is often of limited use in the context of genetic counselling and testing (Wertz & 
Knoppers, 2002). Quality of life studies have only been published for the major subtypes and 
in those, the wellbeing is reduced in afflicted children as well as adults. Physical limitations 
related to the core phenotype is one factor, but treatable manifestations like cramps, tremor 
and fatigue are also major contributors. Social stigma may also lower the individual sense of 
well being (Burns, Ramchandren, Ryan, Shy, & Ouvrier, 2010; Pfeiffer, Wicklein, Ratusinski, 
Schmitt, & Kunze, 2001; Boentert et al., 2010). Private class 5 and class 4 mutations in rare 
CMT genes, for which no natural history studies exist, cause even greater ambiguities 
regarding prognosis. The interpretation of class 3 variants (VUS) often remains indeterminate 
after family investigations. These obscurities may be difficult to convey for the laboratory, 
and difficult to understand for the physicians and their patients.  
 
6 Summary 
The CMT phenotype is the most common inherited neurologic disorder, but it is also 
genetically one of the most multifarious, and with only four exceptions (PMP22dup, MPZ, 
MFN2 and GJB1) the CMT subtypes are individually extremely rare. Furthermore, there are 
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phenotypic overlaps with related and almost equally genetically diverse conditions like 
HSAN, HMN, ALS and HSP. The pathomechanisms of these conditions involve many of the 
same metabolic pathways and some of the same disease associated genes. Diagnostic testing 
of index patients for CMT therefore presents a number of challenges, both for the screening of 
the main bulk of the patient samples, and also for the group prioritized for extended studies. 
Genetic counselling of families with mutations in PMP22dup and other prevalent CMT genes 
are complicated by the large clinical variability. Genetic variants in rare disease associated 
genes, and variants of uncertain clinical significance are affiliated with uncertainties that are 























Aims of these studies 
The Department of Medical Genetics at the University Hospital of North-Norway serves as 
part of the National Neuromuscular Centre and receives samples for genetic testing of 
neuromuscular disorders from all parts of Norway among which CMT testing makes up the 
largest group. This study is based on 559 samples received for CMT testing during the seven 
years from 2004-2010. The overall aim was to improve the diagnostics of inherited 
polyneuropathies. As a part of this effort we defined sub goals as outlined below:  
 
1 Statistical analysis and revision of molecular genetic diagnostics in a population of   
   Norwegian patients with CMT. 
  1.1 Diagnostic testing of index patients 
- Describe the spectrum of genes and mutations involved in Norwegian patients with CMT. 
- Based on the referral forms following the patients; identify factors that are   
   associated with positive and negative genetic findings. 
- Analyse and, if necessary, revise the test protocols and formulate criteria for mandatory    
   information to be obtained before genetic testing for CMT.  
 
  1.2 Molecular genetic family investigations 
- In families of patients with definite or likely pathogenic genetic variants (class 4-5).           
- Give a quantitative estimate of the number of relatives tested, as well as the relative  
       proportions of the indications for testing. 
- Describe the characteristics of the cases within each indication group.  
- In families of patients with genetic variants of unknown clinical significance (class 3). 
- Assess the impact of segregation analyses. 
 
2 Extended studies - identification of the disease gene in a large Norwegian family   
   with a CMT2-like disorder. 
- Describe the clinical and neurophysiologic phenotype in affected patients.  
- Identify the chromosomal region where the disease associated gene is localized. 
- Identify and characterize the gene and the mutation that are associated with the disease.   
 
In part 1.1 we aim at improving the strategy for molecular genetic testing of CMT in 
diagnostic laboratories. It should also be of help in delineating the patient group that could 
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benefit from extended testing at an interdisciplinary neuromuscular clinic. This may be of 
advantage for health services, patients and users of the laboratory as we expect an increase in 
conclusive test results, a decrease in false positive results and a more efficient use of 
resources. Part 1.2 will aid in the assessment and planning of resources needed for family 
studies. In part 2 the purpose was to identify and characterize a new common cause of CMT2 
in Norway. This will allow us to create a new diagnostic test which will benefit patients and 
the results will shed new light and knowledge on the molecular aetiology of CMT2 and 

























Part I - screening of index patients (1.1) and subsequent molecular genetic family 
investigations (1.2) 
 
Clinical investigations, data collection, statistics and endpoint measures 
During the seven years from 2004 to 2010 we received 559 samples with the request to carry 
out molecular genetic testing for CMT (Figure 2). In 472 cases diagnostic testing of index 
patients was called for, but in 37 cases the request was cancelled by the laboratory. In the 
remaining 435 cases tests were performed in compliance with the protocol (see below; 
Molecular investigations) in 298 cases. In 137 cases there were discrepancies from test 
protocol. In that group 2.7 genes were investigated pr. patient on average. We identified a 
sequence variant in 72 index cases. Following family studies for diagnostic, carrier or 
presymptomatic testing were requisitioned for 75 patients belonging to 31 families (43%). We 
also received samples from 12 family members of 10 index patients diagnosed at other 
laboratories. In total, testing of 87 family members from 41 families was requisitioned. 
 
From the laboratory request forms important data were extracted and systematized to examine 
to which extent they modified the outcome of genetic diagnostics. Among others, these 
encompassed the test indication, clinical information, NCS results, age at onset and at testing, 
speciality of the referring physician, family history with regards to mutation status and 
symptoms. The group of index cases that underwent diagnostic testing and the group of 
affected and healthy relatives tested for known family mutations were divided and analyzed 
separately. In part 1.2 the separate variables were assessed and data from the mutation 
positive and the mutation negative patient samples were compared. The Statistical Package 









Figure 2. Flowchart of the investigations performed on 559 samples received for CMT 




Molecular investigations  
Index patients with demyelinating or mixed (axonal and demyelinating) polyneuropathy 
underwent testing with a CMT1 panel containing Multiplex Ligation dependent Probe 
Amplification (MLPA) of the PMP22 region as well as DNA sequencing of the MPZ, EGR2, 
LITAF, NEFL, PMP22 and GJB1 including all coding exons and the adjacent intron 
sequences (Table 2). Requisitions indicating axonal polyneuropathy and those with normal 
NCS results were investigated with a CMT2 panel containing DNA sequencing of the MFN2, 
MPZ, NEFL and GJB1 genes including all coding exons and the adjacent intron sequences. 
Requisitions, in which the type of polyneuropathy was non-specifiable, were categorized as 
559 samples 
received for testing 
with regards to 
CMT. 
87 samples received 
for diagnostic/carrier 
or presymptomatic 
testing for known 
























with the test 
algorithm. 
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“deviation from test protocol” if they were not studied with both the CMT1 and CMT2 test 
batteries. Clinical and family information determined if the GDAP1 gene should be sequenced 
in individual cases. In total 58/435 patient samples from all polyneuropathy groups were 
analyzed. MLPA of MPZ/MFN2 was carried out on 229/435 samples. Relatives were tested 
for the particular sequence variant already identified in the index patient. Genetic variants 
were assessed with the Alamut software (Interactive Biosoftware, San Diego, CA, USA), 
which incorporates data from multiple internet sources, and additional manual interpretation. 
The sequence variants were categorized into five groups that communicate the likelihood of 
their pathogenicity in the range from definitely pathogenic (5) to definitely not pathogenic (1). 
Variants that were determined to be non-pathogenic or likely non-pathogenic (class 1 and 2) 
were designated as negative findings. For variants of uncertain clinical significance (class 3) 
segregation studies of relatives were carried out whenever possible. 
 
Table 2. CMT1, CMT2, CMT4, CMTX and DI-CMT subtypes with gene symbols or loci 
(Bird, 2014).  
 
          *genes analyzed in this study. ** mixed axonal and demyelinating neuropathy 
 






































































Part II – extended studies - identification of the disease locus in a large Norwegian 
family with a CMT2-like disorder. 
 
Patients, clinical investigations and neurophysiologic evaluations 
The subjects of the investigations in part II belonged to an extensive Norwegian “CMT2” 
kindred. The earliest obligate mutation carrier in the part of the family that was described in 
paper 3 was born in 1763. That part of the family spanned over 7 generations. We evaluated 
10 departed and 12 living relatives. Before the project started a meeting with the family was 
arranged, initiated by the family members, The Norwegian Association for Patients with 
Muscle Diseases, The Centre for Rare Disorders at Oslo University Hospital and The 
Department of Medical Genetics, University Hospital of North Norway. During the project 
the family members were updated at re-examination, and through written information. A 
follow up meeting was held at the end of the project and individual results were given upon 
personal request at counselling. The family was thereafter transferred to The Centre for Rare 
Disorders at Oslo University Hospital.  
 
The phenotype in the family was originally categorized as CMT2. In order to obtain a precise 
description of the phenotype 12 family members were examined anew clinically. Nine of 
them also underwent neurophysiologic investigations. NCS of the median and ulnar nerves 
was performed in one arm as well as of the superficial peroneal, tibial, and sural nerves of 
both legs. Needle-EMG was registered in the opponens pollicis, extensor digitorum communis 
and deltoideus posterior muscles in one arm, as well as in the anterior tibial, medial 
gastrocnemius in both legs and lateral vastus in the right leg. Threshold temperatures for 
sensations of cold, warmth, cold-pain and heat-pain were measured at the base of the thumb, 
lateral at the left thigh, at the lower leg and at the back of the foot bilaterally (Thermotest, ® 
Somedic AB, Sweden). Allodynia was estimated by brushing of all 4 limbs. In addition, 




Genome-wide genotyping was executed with Human CNV370 chips (Illumina) with the 
presumption of autosomal dominant inheritance, a penetrance of 95%, a frequency of the 
disease associated allele of 0.0001, and a phenocopy rate of 0.001. Multipoint linkage analysis 
was completed implementing MERLIN (Abecasis, Cherny, Cookson, & Cardon, 2002). 
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About 42,500 markers with a minor allele frequency of >= 0.15 were picked for the study. 
Bidirectional sequencing was executed with BigDye version 3.1 and an ABI 3130xl (Applied 
Biosystems). Analysis of the most likely disease associated gene in the linkage region was 
performed by sequencing of all coding exons in the SOD1 gene in the index patient and 
consecutive segregation studies of the family. PCR amplification and partial sequencing of 


























Summary of papers 
 
Paper I: Diagnostic laboratory testing for Charcot Marie Tooth disease (CMT):  
The spectrum of gene defects in Norwegian patients with CMT and its implications for 
future genetic test strategies. 
We assessed the spectrum of gene defects documented in CMT patients analyzed at The 
Department of Medical Genetics at the University Hospital of North-Norway during the 
course of seven years (2004 – 2010). The information given in 435 requests for diagnostic 
investigations of index patients were assessed retrospectively. Testing was executed according 
to polyneuropathy type; demyelinating/mixed: PMP22 duplication, MPZ, EGR2, LITAF, 
NEFL, PMP22, GJB1, axonal: MFN2, MPZ, NEFL, and GJB1. Clinical details such as family 
history, age at first symptoms and age at testing, clinical details and results on nerve 
conduction studies (NCS) were registered. The group consisting of cases with a positive 
finding and the group with mutation negative cases were compared utilizing a statistical tool 
(SPSS 20.0). Seventy-two (16.6%) genetic variants of uncertain (12), likely (12) or certain 
(48) pathogenicity were detected. Most (94.6 %) of the mutation positive index patients 
experienced disease onset prior to 50 years of age. In total 31.2 % of the samples received by 
the laboratory belonged to index patients with onset after 50 years of age however. Few 
positive findings were made in that group. PMP22 duplications and sequence variants in 
MPZ, GJB1 and MFN2 composed 95.8 % of the positive findings. The mutation detection 
rates within the polyneuropathy types were; demyelinating 33.8 %, mixed (both 
demyelinating and axonal) 29.0 %, axonal 8.8 %, and unspecified 16.5 %. A classical CMT 
phenotype was indicated in all cases with a positive finding and an acceptable detection rate 
was also achieved in requests with little complementary information. In contrast no findings 
were made in cases where the requests indicated atypical CMT, a more complex phenotype or 
a primary assumption of another condition. The inheritance patterns estimated from the 
requests, and the inheritance patterns deducted from the detected gene defects did not 
correlate well. The study revealed 11 novel sequence variants that had not been described in 
the HGMDp database version 2013.2. These were detected in the MPZ gene (c.679A>T, 
c.368G>T, c.410G>A), in NEFL (c.1027_1029del), GJB1 (c.775del), and in the MFN2 gene 
(c.2146_2148dup, c.250A>G, c.612T>A, c.653T>C, c.692C>T and c.1921T>C). The high 
prevalence of PMP22dup, and sequence variants in MPZ, GJB1 and MFN2 indicate that the 
first screening of external samples may be limited to the four most frequent genes. The 
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decision on which genes to test should primarily be founded upon NCS results. These results 
also support a more strict practice for testing of index patients with onset after 50 years of age 
with this gene panel. The same applies for patients with a more complex phenotype, atypical 
CMT, or a primary assumption of a different diagnosis. These latter groups can be met with 
higher demands regarding family history and clinical details, but also with a potential referral 
to extended investigations. This also applies for patients with a negative result for the four 
most prevalent genes. The extended investigations should involve an evaluation at a 
neuromuscular clinic that is capable of targeted molecular genetic analysis of “rare” CMT 
genes as well as linkage studies and diagnostics utilizing next generation sequencing 
technology 
 
Paper II: Segregation analysis in families with Charcot-Marie-Tooth disease allows 
reclassification of putative disease causing mutations. 
During the years from 2004-2010 we identified 72 genetic variants of definite (48), likely (12) 
or uncertain (12) clinical significance in index cases with CMT. Our intention was to evaluate 
the follow up investigations with family studies, including the relative proportions of the 
various test indications as well as the test results and reported clinical details. The main 
objective however, was to assess the family investigations executed as part of the evaluation 
of variants of unknown pathogenicity. We analyzed 87 requests for testing of relatives akin to 
41 index patients, including 12 family members of 10 index patients diagnosed at other 
institutions. The mean number of relatives investigated was 2.1 per index patient. Diagnostic 
investigations of afflicted relatives for genetic variants of definite/likely pathogenicity were 
completed in 41 relatives from 29 families. Mean age at investigation was 27.6 years (range 2 
months – 78 years). Six family members (14.6%) tested negative whereas 35 relatives from 
26 families tested positive. NCS results were reported only in 28.6 % of the afflicted family 
members and in the greater part (65.7 %) only limited clinical information was given. The 
unexpectedly high rate of normal results on diagnostic testing of afflicted relatives 
underscores the need for an accurate clinical diagnosis, even in that group. Presymptomatic 
testing of healthy relatives for genetic variants of definite/likely pathogenicity was executed 
in 20 relatives from 12 families. Mean age at investigation was 37.0 years (range 2 – 92 
years). The low detection rate in the presymptomatic testing group (21 %) is related to the 
high average age at testing, de novo mutations, and investigations of family members who 
were not first degree relatives. The de novo mutations comprised a c.490C>T missense 
substitution in GJB1. Prenatal testing was requested by one of nine females at fertile age (21-
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42 years) carrying a genetic variant of certain pathogenicity. Twenty-two relatives (9 
clinically affected) from 8 families were included in the family investigations executed as part 
of the evaluation of VUS. Mean age at investigation was 44.7 years (range 3 – 66 years). All 
except two cases were more than 30 years of age. Three instances of de novo MFN2 sequence 
variants were revealed in two patients with a classic CMT2 phenotype (c.2146_2148 dup and 
c.692C>T) and in one patient with a severe phenotype (c.250A>G). That led to the upgrading 
of the classification from uncertain to likely for two of the sequence variants. Moreover, 
following segregation studies, one MFN2 substitution (c.1709A>G) was downgraded from 
uncertain to unlikely pathogenic, and one MPZ substitution (c.103G>A) was upgraded from 
unknown to likely pathogenic.  
 
Paper III: Hereditary motor neuron disease in a large Norwegian family with a “H46R” 
substitution in the superoxide dismutase 1 gene. 
The study of an extensive “CMT2” kindred with whole genome linkage analyzes and 
haplotype investigations pinpointed a 1.9Mb candidate region on chromosome 21. SOD1 was 
the most likely candidate gene and follow up Sanger sequencing showed a c.140A>G 
(p.His47Arg, alias “H46R”) substitution. The disease was transferred in an autosomal 
dominant way in the family and we investigated 10 departed and 12 living relatives. Amongst 
the departed one case of likely non-penetrance in an obligate mutation carrier was observed. 
The 12 living relatives were reassessed clinically and 9 individuals were studied with NCS, 
EMG, thermotest and evaluations of allodynia and hyperalgesia. The mean age at disease 
onset was 42.5 years (22-65) and the initial symptom was distal weakening of a leg in all 
cases that had specific information. The impairments progressed to involve the hands years 
later. Seven of the 12 individuals developed wheelchair dependency after a mean duration of 
9.7 years. Sensory investigations were normal with the exception of one individual who had 
increased vibratory thresholds beneath the knees. Some manifestations indicating an 
implication of upper motor neurons were observed in 3 patients demonstrating a certain, and 2 
patients a possible Babinski’s sign. Spasticity or increased reflexes were not observed 
however, and the upper motor neuron involvement was not more pronounced than what has 
been described in connection with dHMN. Cognitive decay, respiratory failure or bulbar 
symptoms were not detected. Bone fractures were registered in 6 patients, many in association 
with minor trauma, perhaps caused by osteoporosis due to inactivity. Average period from 
onset of the first symptoms to passing was 29 years (11-51). NCS exhibited reduced 
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amplitude of motor nerves in the lower extremities indicating axonal motor involvement. 
Indication of sensory involvement of the upper limbs was not registered. Some patients 
exhibited signs of axonal involvement of the sensory nerve fibres in the lower limbs however. 
On EMG extensive neurogenic alterations with denervation activity, pathological motor unit 
potentials and complex repetitive discharges in numerous muscles were registered, much in 
compliance with observations known from motor neuron diseases. Only few muscles 
demonstrated fasciculation potentials however. Six patients had heightened thresholds for 
cold detection implying a small fiber involvement. We also tested all family members for the 
chromogranin B (CHGB) variant c.1238C>T (p.Pro413Leu) to study the possible association 
with disease onset, none of the relatives was carriers however. The diagnosis was altered to 
dHMN after the clinical reassessment due to the scarcity of sensory symptoms and findings. 
Later on the involvement of proximal muscles made the clinical picture more consistent with 
the ALS phenotype. Moreover, the one-sided onset with weakening of a calf muscle is not to 
be anticipated in a dHMN/dSMA. The p.His47Arg substitution has mainly been published in 
Japanese patients, but the description of this sizable kindred demonstrated that it has been 
underrated as a cause of HMN in Norway, and possibly also in other populations. The kindred 
exemplify the variety of non-demyelinating inborn neuropathy phenotypes that have been 
consolidated under the CMT2 umbrella. We therefore propose that patients with a phenotype 
starting with adult one-sided weakness in a calf muscle advancing to a distal hereditary motor 














Results and discussion 
 
1 The impact of clinical, nerve conduction studies, and family information on genetic 
diagnostic testing of index patients with CMT 
The conventional algorithms for molecular genetic CMT testing presuppose accurate and 
complete inputs concerning clinical symptoms, NCS and family history. For external samples 
however, such precision and fullness of the input may not always be assumed. In spite of 
obvious differences between the carefully selected patient cohort ascertained at 
neuromuscular clinics, and the heterogeneous cohort of external samples analyzed at 
diagnostic laboratories, they have traditionally been handled as if they were the same. 
Thorough descriptions of the external sample cohort have been absent, although it 
quantitatively represents the largest group. Our intention was to do a complete evaluation of 
the diagnostic testing performed on our CMT samples, which are requested by various 
external medical doctors. 
 
Firstly, based on the requisitions, we aimed at recognizing elements that were associated with 
positive and negative test results. In paper I we included 435 afflicted index patients 
genetically tested for CMT and as a result 72 positive genetic findings were documented. 
Close to half of the positive results were obtained amid requests indicating a clear suspicion 
of CMT, but with little specified supporting information. This group of requests was 
numerically the largest. The yield of positive findings was clearly higher amongst requests 
giving a more thorough description of a classical CMT phenotype, particularly when 
additional features known to be associated with the most prevalent CMT genes were 
specified. The requests specifying a particularly severe phenotype showed the lowest 
detection yield. Seventy-three requests stated symptoms indicating atypical CMT, a more 
complex phenotype, or a primary suspicion of a differential diagnosis. In that group no 
positive findings were made with the gene panel applied in this study. 
 
These results support an approach of limited testing (PMP22, MPZ, GJB1, MFN2) of external 
patients with a clearly stated suspicion of CMT, but with few clinical details supporting the 
diagnosis, The evaluation of  PMP22dup and sequence variants in GJB1 are also 
straightforward in most cases. A subsequent summoning of complementary information or the 
initiation of segregation studies is therefore mostly not necessary. The low yield of positive 
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findings associated with requests that indicate a primary suspicion of other diagnoses supports 
a restrictive policy for the gene tests applied in this study. Some of these patients should 
rather be examined clinically and neurophysiologically at a neuromuscular clinic, before 
extended molecular genetic testing. The group of index patients with severe symptoms 
reported in paper I was small (14 patients) and only one positive finding was documented (a 
patient homozygous for the PMP22 duplication). No positive results were obtained upon 
testing of EGR2 or amongst 58 patients selected for GDAP1 testing. This would suggest that 
the causes for recessive CMT in Norway are still elusive. However, after the completion of 
this study several cases associated with mutations the SH3TC2 gene (CMT4C), were 
identified. From the cohort of CMT patients received by our Department before 2013, thirty-
two affected index patients were selected for SH3TC2 testing. The selection was based on 
individual assessment of the cases, but a severe phenotype with early disease onset, scoliosis, 
foot deformities, demyelinating polyneuropathy and a family history compatible with 
autosomal recessive inheritance were important criteria. Twelve patients (37.5 %) were 
diagnosed with CMT4C. Eight were homozygous for the common nonsense variant 
c.2860C>T, p.Arg954*, four were compound heterozygous for the c.2860 C>T variant and a 
missense variant (c.798T>C, c.3511C>T, c.956G>T) (unpublished results). This indicates that 
CMT4C may be a common cause of recessive CMT in Norway. Dominant cases with 
mutations in MPZ and MFN2 would have been expected in the severely affected group if the 
cohort had been larger. In fact, one severe case in an infant from a DSS family with a MPZ 
substitution, as well as a severe case with a de novo substitution in MFN2 was described 
amongst the relatives reported in paper II. 
 
The results in paper I clearly confirmed an association between a positive family history and a 
positive genetic test result. In the prevailing test algorithms however, assumptions about the 
inheritance patterns are often used to select genes for testing (England et al., 2009; Saporta et 
al. 2011). The quality and amount of specifications regarding family history in the requisition 
forms varies greatly, they are often insufficient, or more concerning, inaccurate. We 
demonstrated a poor correlation between the inheritance patterns assumed from the 
requisitions, and the correct transmission form documented by the identified gene defect. 
Testing of GJB1 is superfluous in families with unambiguous male to male transmission 
however. Family histories compatible with autosomal recessive inheritance should create 
awareness that the causative mutation may well be found outside the four most prevalent 
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CMT genes. Amongst ethnic Norwegians SH3TC2 is the most likely candidate gene in such 
cases.  
 
A clear association between the various types of polyneuropathy indicated by NCS, and the 
likelihood of obtaining a positive test result was also confirmed in paper I. The highest 
detection rate was observed in the demyelinating and mixed (demyelinating and axonal) 
polyneuropathy groups (33.8 %; 29.3 %). The lowest proportion of positive findings was 
found in the axonal polyneuropathy group (8.8 %). In retrospect, the observed gene defect 
was compatible with the polyneuropathy type indicated on the requisition form in all cases. 
The prevailing test algorithms are predominantly based on the CMT classification which 
relies on assumptions about the inheritance pattern as well as the NCS result. In paper I we 
demonstrated that the majority (63.9 %) of our external samples could not be categorized 
according to those criteria, primarily due to insufficient family details, more scarcely due to 
the absence of NCS results. The practicality of the CMT classification was diminished even 
further by the low correlation between the transmission modes deduced from the requisitions 
and the inheritance patterns documented by the identified gene defects. We concluded that the 
NCS results alone are far more robust and precise in the prioritization of genes to be analysed 
in external samples. Of note, index patients with requisitions lacking NCS results obtained a 
positive result in 16.5 % of the cases, equal to the proportion detected in the cohort of index 
patients as a whole (16.6 %). We did however spend more resources on that group, because 
more genes had to be analyzed according to protocol.  
 
During the years we have noticed that a major part of the requisitions for CMT testing 
received by our laboratory are associated with individuals that are of some age. In paper I we 
documented that 53 % of the requisitions belonged to patients that were > 50 years when the 
blood was sampled. However, 23 positive findings were observed in this group, presumably 
due to a delay from age at onset to age at testing. When we evaluated the group with known 
age at onset in isolation (52.6 %), we could show that virtually all positive results were 
documented in indexes with onset < 50 years of age (95.8 %). Of note, in the selected group 
with known age at onset (231/435), approximately one third (31.2%) of the requests 
concerned indexes with onset > 50 years of age. Only one certain finding (PMP22dup) was 
found amongst those 72 patients (and one VUS in MPZ). Most of the patients with onset > 50 
years of age had either an axonal polyneuropathy (59.7 %) or no NCS results at all (21 %), 
many combined with the absence of a specified family history. Hence phenocopies most 
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likely constitute a major fraction of this group. All in all these data support a more restrictive 
practice for the gene tests applied in this study for patients with onset > 50 years of age. 
Requisitions that are well founded based on thorough clinical information, specified family 
details and NCS should be tested regardless of age at onset however. 
 
The requisition forms of relatives of index patients (paper II) mostly contained only little 
clinical information. To some surprise, 6/41 affected family members (14.6 %) tested negative 
for the family mutation. In those cases clinical details were limited and NCS results were not 
reported. Amongst the relatives with a positive test result, a female with a c.490C>T 
(p.Arg164Trp) substitution in the GJB1 gene had tremor from early childhood, particularly of 
the head, muscular cramps and fasciculation’s in addition to the polyneuropathy. Dejerine-
Sottas syndrome (DSS) was reported in a family with a c.368C>A (p.Gly123Val) substitution 
in the MPZ gene.  Requisition forms of affected relatives that were supplied with detailed 
clinical information (10/41); all described a classic phenotype concordant with the index 
patient group. The investigation of relatives could potentially reveal cases with uncommon 
phenotypes due to a lower threshold for testing, but this was not the case in our cohort.  
 
2 The relative distribution of gene defects among mutation positive index patients in our 
population 
Secondly, we wanted to characterize the spectrum of sequence variants and genes implicated 
in CMT in Norway. The mutation detection rate amongst index patients with available NCS 
results were 33.8 % for the demyelinating, 29.3 % for the mixed (axonal and demyelinating), 
and 8.8 % for the axonal polyneuropathies, as compared to 16.6 % for the total group. Almost 
all positive findings were made up by PMP22dup and sequence variants in MPZ, GJB1 or 
MFN2. None of the index patients reported in paper I carried deletions/duplications of the 
MPZ gene. Moreover, sequencing of LITAF/SIMPLE, EGR2, PMP22 and GDAP1 showed 
negative results in all tested cases, implying that sequence variants in these genes are rare 
causes of CMT in Norway. All in all we found 11 new sequence variants not described in the 
HGMDp database version 2013.2. These were discovered in MPZ (c.679A>T, c.368G>T, 
c.410G>A), NEFL (c.1027_1029del), GJB1 (c.775del), and MFN2 (c.2146_2148dup, 
c.250A>G, c.612T>A, c.653T>C, c.692C>T and c.1921T>C). 
 
The reported frequency and spectrum of sequence variants and genes implicated in CMT 
varies considerably across different studies and populations. The proportion of gene defects in 
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CMT1 spans from 23.3% to 60.7% for PMP22dup (average 41.8%), from 2.4% to 13.0% for 
MPZ (average 5.0%), and from 5.5% to 25.8% for GJB1 (average 8.8%) (Bort et al., 1997; 
Choi et al., 2004; Mostacciuolo et al., 2001; Nicholson, 1999; Silander et al., 1998; Abe et al., 
2011; Mersiyanova et al., 2000; McCorquodale, III et al., 2011). This might mirror unequal 
frequencies of particular CMT associated gene defects in various populations, but perhaps 
even more so, differences in sampling methods and strategies for testing and reporting of the 
results. Notably, the ways the patients are ascertained appear to influence the detection 
frequency to a large extent. The patient cohort sampled at neuromuscular clinics have a 
significantly higher fraction of mutation positive cases than the heterogeneous patient group 
tested as external samples (Saporta et al., 2011; Murphy et al., 2012). The comparatively low 
detection frequencies in our cohort ought to be interpreted bearing this in mind. However, the 
PMP22dup frequency (18.7%) is even lesser than anticipated relative to the prevalence of 
MPZ mutations (6.0%) and GJB1 mutations (6.7%). A comparable prevalence of PMP22 
duplications (13.6 %) was reported in families with CMT amongst the inhabitants of 
Akershus County, Norway (Braathen, 2012). The results may imply that we obtain fewer 
CMT1A patients at our laboratory, relative to the other gene defects. In comparison, the 
requested family investigations exhibited a tendency in the same direction; when the index 
patient had a PMP22dup subsequent testing of relatives was requested in 23 %, as compared 
to 60 % for GJB1, 64 % for MPZ and 42 % for MFN2.  
 
3 Revision of the test protocol and criteria for the implementation of genetic testing of 
index patients – summary  
Finally and based on the project results, we aimed at revising our CMT test protocol and 
formulate criteria for the information compulsory for genetic testing. In the meantime 
however (the project started in 2010) a radical technological transformation occurred within 
the field of medical genetics with the introduction of massive parallel sequencing 
technologies. At first it was introduced as a new and potent research tool, but it was also soon 
applied by diagnostic laboratories as well. Extensive panels of known disease associated 
genes bypass some of the technological and ethical challenges that still apply, and are 
therefore most widely used at present. With time and with increasing experience though, these 
challenges will be overcome and exome/whole genome sequencing will become standard, 




At this point in time, and in our experience as a small/medium size diagnostic laboratory 
primarily testing external samples, it is still appropriate to filter the incoming requests and to 
investigate them in a stepwise manner. The combination of scarce clinical information (such 
as “polyneuropathy”) and a certain genetic finding (such as PMP22dup or mutations in GJB1) 
is manageable for diagnostic laboratories. Extensive genetic testing of uncertain phenotypes 
(clinical group 1 in our study), however, would inevitably produce a large group with the 
combination of an uncertain phenotype and an uncertain genetic finding (class 3 variants). A 
professional handling of these cases requires a posterior summoning of additional clinical 
information and in many cases also the initiation of segregation analyses. In paper 1 we 
documented the poor compliance from referring physicians that initially had sent a request 
form falling within clinical category 1. Certain findings in rare disease associated genes 
and/or in atypical phenotypes should also be documented well. The principle question is if 
this information should be sampled before or after the investigation with NGS technologies 
(Vasli et al., 2012; Vasli & Laporte, 2013).  
 
On this backdrop we propose a two-tier strategy, the first tier is intended for referral centres 
similar to ours, receiving blood or DNA, not patients. The choice of genetic tests in this 
context should chiefly be based on NCS. Index cases with demyelinating or mixed (axonal 
and demyelinating) polyneuropathy and patients where NCS is not specified, ought to be 
investigated with PMP22 MLPA and sequencing of MPZ and GJB1. Index cases with axonal 
polyneuropathy should be investigated with sequencing of MFN2, MPZ and GJB1. This 
strategy would reduce labour substantially and still only miss about 4 % of the positive 
findings in our cohort. An analogous proposal was forwarded by a UK group (Murphy et al., 
2012). The results of our studies advocate a stricter routine for genetic investigations of cases 
with onset > 50 years, cases with an atypical or more complex phenotype, or requisitions 
primarily indicating the suspicion of a differential diagnosis (at least for the genes tested in 
this study). These particular cases can be met with higher demands regarding the family 
history and clinical details, but also by a potential transferral to the second tier of the 
investigations. The second tier should include an interdisciplinary evaluation at a 
neuromuscular centre that is able to perform detailed clinical and neurophysiologic 
investigations, targeted molecular genetic testing of rare disease associated genes, NGS and 
(for some cases) linkage analyses or analyses of CNV (copy number variation).  
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4 The application of presymptomatic and prenatal testing for genetic variants of definite 
or likely clinical significance  
The intention of the study leading up to paper II was, broadly defined, to evaluate the 
molecular genetic family investigations following a diagnostic finding in an index patient. We 
wanted to describe the relative proportions of the different indications for testing as well as 
the results, and the reported clinical information. 
 
In total, presymptomatic testing was requested for 20 healthy relatives of afflicted index patients 
harbouring sequence variants of known or likely pathogenicity. A positive finding was detected in 
21%. The low rate of positive findings is likely due to the fact that; several of the tested family 
members were adults (average age 37 years), three second degree relatives were included and two 
patients turned out to harbour de novo mutations (a PMP22 duplication and a c.490C>T missense 
mutation in GJB1). De novo duplications of the PMP22 region are common, but in GJB1 de novo 
sequence variants are allegedly rare (Meggouh et al., 1998). Six of the requests for 
presymptomatic testing concerned minors aged 15 years or younger. This seems to contradict 
recommendations for genetic testing of benign conditions with limited available treatment 
measures. Four of the cases were requested by different departments of medical genetics, two 
were ordered by our own department. Data that potentially could elucidate the backgrounds for 
these decisions were not available to us, but they are all founded on individual considerations by 
various expert professionals, and in that way they represent common practice.  
 
Prenatal diagnostic testing is available in childbearing carriers of genetic variants of certain 
pathogenicity. Only 1/9 healthy female relatives at fertile age wished prenatal testing however 
(paper II). Amongst 72 affected index cases (paper I), 15 women aged 20 - 46 years 
harboured class 4/5 variants. None of these desired prenatal testing. Thus, in our experience, 
prenatal diagnostics is rarely applied for CMT in Norway. 
 
5 Evaluation of the molecular genetic family investigations initiated after the 
identification of genetic variants of unknown clinical significance (class 3) 
The main objective of paper II was to evaluate the family studies executed in order to assess 
sequence variants of uncertain pathogenicity (VUS). We included 22 relatives (9 afflicted) 
from 8 families. The mean age was 44.7 years. In 4 of the 8 families classifications were 
adjusted, much due to the documentation of multiple de novo mutations in MFN2. A 
comparatively high occurrence of de novo sequence variants in MFN2 has been observed in 
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other patient populations, mainly with severe symptoms. The de novo occurrence of 
c.280C>T has been reported multiple times (Zuchner et al., 2004; Verhoeven et al., 2006; 
Chung et al., 2006; Cho, Sung, Kim, & Ki, 2007). Two of our patients with spontaneous 
MFN2 mutations (c.2146_2148dup and c.692C>T) and a disease onset before the age of 10 
years showed a classical CMT2 phenotype however. This verifies that de novo MFN2 
sequence variants are also recurrently documented in patients with a milder phenotype 
(Braathen, Sand, Lobato, Hoyer, & Russell, 2010). The third de novo case (c.250A>G) and a 
disease onset before the age of 10 years exhibited a severe phenotype more in compliance 
with the early onset group described elsewhere (Verhoeven et al., 2006; Chung et al., 2006; 
Chung et al., 2010). Posterior to segregation studies one MFN2 mutation (c.1709A>G) was 
reclassified from uncertain to unlikely pathogenic and one MPZ mutation (c.103G>A) was 
upgraded from uncertain to likely pathogenic.  
 
Segregation analysis is only one of several tools used in the evaluation of variants of uncertain 
pathogenicity. The assessments include the sampling of documentation from several sources 
in an attempt to build up evidence for or against pathogenicity. The effort to quantify 
uncertainty is neither standardized nor unproblematic, and final proof for or against the 
clinical significance of a variant is not obtained (Gomez Garcia et al., 2009). Cancer is the 
disease group where most work has been done in this regard. One of the main outcomes there 
is to decide whether possibly life-saving prophylactic treatment shall be initiated. A larger 
risk of over-interpretation may be tolerable in that context. Cancer susceptibility genes such 
as BRCA1/2 are also amongst the most extensively studied. As a consequence, a massive 
amount of data has been accumulated that can be incorporated into the evaluation of new 
sequence variants (Eggington et al., 2013). In contrast, the main outcome in benign diseases 
without causal treatment options like CMT is a precise diagnosis, accurate genetic counselling 
and potentially prenatal and presymptomatic testing. Most of the CMT subtypes are rare or 
extremely rare, and associated with genes that are poorly studied compared to the common 
cancer susceptibility genes. Less evidence is therefore available for the evaluation of new 
variants complicating the application of Bayesian approaches.  
 
Although the introduction of 5 interpretation classes may seem aspiring, we have chosen to 
implement them knowing that many of the a priori class 3 variants will and should remain in 
the VUS group, even after follow up investigations (Plon et al., 2008). This is in compliance 
with the recommendations from The Norwegian Society of Human Genetics. The ACMG 
 47
Laboratory Quality Assurance Committee proposed an analogous classification that 
additionally included a sixth category for low penetrant alleles (Richards et al., 2008). 
Guidelines approved by the UK Clinical Molecular Genetics Society proposed 4 interpretation 
classes in the range; not, unlikely, likely and certainly pathogenic (Bell, 2007). The advisory 
groups assent with one another that uncertainties associated with the genetic variants must be 
disclosed to the clinicians and their patients. Furthermore, it is essential that class 3-5 
sequence variants are reported, particularly in rare disorders like CMT. 
 
6 The clinical and neurophysiologic phenotype in patients with CMT2-like-disease  
In paper III we studied a large Norwegian kindred with a phenotype that for decades had been 
labelled as CMT2. Extensive clinical and neurophysiologic examinations of afflicted relatives 
were executed in order to achieve an accurate description of their phenotype.  
  
At the age of 42.5 years on average (range 22-65) the mutation positive family members 
developed weakness distally in a leg. In relatives with sufficient clinical data the initial 
weakness was situated in one of the calf muscles in all cases. Dependency on a wheelchair 
occurred after 9.7 years (range 4-20), and weakness in the hands after 10.3 years (range 1-20) 
on average. The stretch muscles of the wrists and digits were (relatively) preserved, even late 
in the disease course. Bone fractures (six cases) and facial weakness (one case) were 
additional traits registered. The manifestation of bulbar symptoms however, was not found 
and none of the relatives were in need of ventilation support. The average time from the initial 
symptoms until departure was 29 years (range 11-51 years).  
 
The NCS first and foremost displayed signs implying axonal motor nerve involvement, but 
also demonstrated the involvement of axonal sensory nerves in the legs. The EMG recorded 
signs indicating subacute and chronic neurogenic pathologic processes compatible with motor 
neuron disease, but hardly any fasciculation potentials as opposed to what is usually 
registered in ALS (Wijesekera et al., 2009; Douglass, Kandler, Shaw, & McDermott, 2010). 
Some signs indicating sensory as well as small fibre (mainly cold) involvement was registered 
with Thermotest. Earlier reports have observed the same in up to one third of the sporadic 
cases with ALS. These findings might be more evident in patients with SOD1 associated 
disease (Hammad, Silva, Glass, Sladky, & Benatar, 2007; Rezania et al., 2003). 
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The kindred reported in paper III was presented to, and considered by our neuromuscular 
clinic as a CMT2 family as the signs were distal onset with (relatively) slow progression, 
discrete UMN signs and the nonappearance of bulbar symptoms. On re-investigation, the 
registration of few (or none) sensory symptoms did not comply with CMT and the diagnosis 
was altered to dHMN. The diagnosis was still in compliance with the long survival that all 
members of this family experienced. The EMG however, registered findings compatible with 
motor neuron disease, and cases with advanced disease exhibited prominent proximal 
involvement in agreement with ALS. The asymmetry of the initial symptom with paresis in a 
calf muscle also separated the phenotype from dHMN/dSMA or CMT2. The phenotypic 
divergence of SOD1 associated disease that this family demonstrated has also been linked to 
multiple other genes involved in diseases involving neurons with long axons. The phenotypes 
associated with the p.Pro56Ser substitution in VAPB for instance, range from ALS, over 
atypical ALS to late onset SMA (Nishimura et al., 2004; Millecamps et al., 2010). SETX 
mutations have been revealed in cases with benignant autosomal dominant juvenile ALS 
(ALS4), dHMN type II and sporadic ALS (Chen et al., 2004; Zhao et al., 2009). Of note, the 
absence of UMN involvement as a trait does not necessarily correlate with a benign disease 
course in SOD1 associated disorders (Cudkowicz, McKenna-Yasek, Chen, Hedley-Whyte, & 
Brown, Jr., 1998). 
 
7 Characterization and discussion of the mutation that is associated with the disease in 
the “CMT2” family 
In paper III we used extended studies, including linkage analysis; to identify the disease 
associated locus and the causative gene in a kindred with a CMT2-like phenotype, but without 
carriers of sequence variants in the most prevalent CMT2 genes. 
 
Genome-wide linkage testing with SNP array genotyping and consecutive haplotype analysis 
pointed to a 1.9 Mb area on chromosome 21 harbouring only 7 genes. SOD1 was the most 
conspicuous candidate gene and we therefore progressed directly to Sanger sequencing which 
revealed a c.140A>G substitution resulting in p.His47Arg. The mutation segregated with the 
trait in the family. Moreover, the c.140A>G substitution has previously been defined as 
disease associated in multiple Japanese families with a resembling phenotype (Aoki et al., 
1994; Ohi et al., 2002), thus the substitution was clearly the cause of the disease in this 
kindred. However, as opposed to the publications from Japan none of the Norwegian patients 
exhibited bulbar symptoms.  
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The count of published sequence variants in SOD1 surpasses 170, many are of unknown 
pathogenicity (Felbecker et al., 2010) (www.alsod.iop.kcl.ac.uk). Some are coupled with 
rapidly developing disease (survival < 2 years), others with a more classic type or a 
comparably benevolent disease course (survival > 5 years). The p.Asp91Ala substitution for 
instance is frequent in some areas of Scandinavia and leads to a relatively benign phenotype 
in homozygous cases (Andersen et al., 1996). As far as we know, the affected relatives 
presented in this work have the lengthiest average duration from onset to departure published 
in connection with any SOD1 mutation (paper III). 
 
Probable non-penetrance in a female obligate mutation carrier was documented as several 
family members described her as unaffected until her passing at the age of 79. That, together 
with the outspread time of onset amongst the afflicted relatives clearly suggested an 
implication of modifying factors, as suspected in other cases of SOD1 associated disease 
(Parton et al., 2002). The p.Pro413Leu substitution (c.1238C>T) in the Chromogranin B gene 
(CHGB) has been linked to an earlier disease onset in patients afflicted with sporadic 
amyotrophic lateral sclerosis (Gros-Louis et al., 2009). Efforts to replicate the association 
have however failed (Blasco et al., 2011; van Vught, Veldink, & van den Berg, 2010). The 
extensive intrafamilial variation in age at manifestation of the first symptoms invited an 
evaluation of the potential modifying role of the p.Pro413Leu substitution in this kindred. 
None of the relatives turned out to be carriers however and we could therefore not contribute 
to a further clarification of the modifying role of the p.Pro413Leu substitution.  
 
Even if the greater number of reports on the p.His47Arg substitution describes patients of 
Japanese ancestry, single patients of Pakistani, German and North American descent have 
also been published (Holmoy, Bjorgo, & Roos, 2007; Rabe et al., 2010; Radunovic & Leigh, 
1996). It remains to be shown if this is due to recurrent mutations or to (an) ancient common 
founder(s). It is possible that the c.140A>G allele (p.His47Arg) is underrated as agent of a 
CMT2/HMN/SMA-like phenotype in Norway, and this may also apply for other populations. 
Therefore individuals with adult manifestation of one-sided weakness in a calf muscle 
advancing to a distal hereditary motor neuropathy-like phenotype, ought to be considered for 




8 Future challenges 
Diagnostic testing of index patients for CMT in it selves presents multiple challenges with 
regards to the screening of the main bulk of the patient samples, as well as for the group 
prioritized for extended studies. The patient group is heterogeneous and the cohort 
investigated at neuromuscular clinics, and the external samples investigated by diagnostic 
laboratories differ significantly. Extended studies now have the capacity to detect rare, 
extremely rare and even new disease associated genes; the latter group may be categorized as 
research. This development should be accompanied by the evolvement and strengthening of 
national and international registers and quality control. The new NGS technology will provide 
new insights into the disease mechanisms that lead to CMT and other conditions 
implementing neurons with long axons, and eventually also effective treatment measures. 
Neuromuscular centres should aim at having patients ready for relevant clinical trials and 
treatments as they develop. Broad diagnostic screening with new technology will more often 
identify disease associated genes that primarily are associated with other disease classes than 
originally anticipated. Genetic counselling of family members for private class 5 and class 4 
mutations in rare genes for which no natural history studies exist are associated with 
ambiguities regarding prognosis. Challenges also adhere to genetic variants of unknown 
pathogenicity and it is important that they are published in relevant databases for future use. 
Last but not least, the genetic counselling capacity, and expertise, should be scaled up to 
maintain a proportionate relationship between the increased capacity for diagnostic testing of 
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